A Multicentre Randomized Clinical Trial on Efficacy and Safety of Huxin Formula in Patients Undergoing Percutaneous Coronary Intervention

Table 1

Inclusion and exclusion criteria.

Inclusion criteria; (1) Age 40 to 75 without gender limitation; (2) Patients who meet the diagnostic criteria of unstable angina or myocardial infarction; (3) Patients who were diagnosed as “deficiency of heart-QI and phlegm stasis-bizu” according to traditional Chinese medicine (TCM); (4) One week after PCI; Exclusion criteria; (1) Patients who have acute myocardial infarction or severe heart failure (cardiac function class IV according to the cardiac function standard of New York Heart Association and the left ventricular ejection fraction ≤30% by heart color Doppler); (2) Patients who have severe liver and kidney dysfunction (serum alanine aminotransferase > three times the normal cap and/or plasma creatinine ≥442 umol/L); (3) Patients who have cancer or active gastrointestinal bleeding; (4) Patients with mental illness; (5) Patients who were pregnant or breast-feeding; (6) Patients who have medical history of CABG and undergo PCI in vascular bridge; (7) Patients with stable angina